Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Lowered by Handelsbanken Fonder AB

Handelsbanken Fonder AB cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.0% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 83,640 shares of the biopharmaceutical company’s stock after selling 3,461 shares during the quarter. Handelsbanken Fonder AB owned about 0.08% of Regeneron Pharmaceuticals worth $87,926,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of REGN. Brown Lisle Cummings Inc. boosted its position in shares of Regeneron Pharmaceuticals by 18.2% during the second quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 10 shares during the period. Sachetta LLC boosted its position in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares during the period. Team Hewins LLC grew its stake in shares of Regeneron Pharmaceuticals by 2.5% in the first quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock worth $434,000 after purchasing an additional 11 shares in the last quarter. Angeles Wealth Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 3.5% in the first quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock worth $313,000 after purchasing an additional 11 shares in the last quarter. Finally, Western Financial Corp CA increased its holdings in shares of Regeneron Pharmaceuticals by 0.7% during the second quarter. Western Financial Corp CA now owns 1,819 shares of the biopharmaceutical company’s stock valued at $1,912,000 after purchasing an additional 12 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

REGN has been the subject of several research analyst reports. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 25th. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Guggenheim raised their price objective on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Leerink Partners reaffirmed a “market perform” rating and set a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Finally, Barclays lifted their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $1,119.00.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,866 shares of the company’s stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the transaction, the executive vice president now owns 37,937 shares in the company, valued at approximately $41,311,496.15. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares in the company, valued at $4,498,280. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph J. Larosa sold 1,866 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the completion of the sale, the executive vice president now owns 37,937 shares of the company’s stock, valued at $41,311,496.15. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 8,033 shares of company stock worth $9,399,345. 7.48% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Stock Down 0.2 %

Shares of Regeneron Pharmaceuticals stock traded down $1.77 during midday trading on Friday, hitting $1,012.82. The company’s stock had a trading volume of 1,071,799 shares, compared to its average volume of 491,440. The firm has a market capitalization of $111.60 billion, a P/E ratio of 29.92, a PEG ratio of 3.56 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,211.20. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The stock has a 50-day simple moving average of $1,125.65 and a 200-day simple moving average of $1,037.49.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period last year, the company posted $8.79 EPS. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.